Skip Nav Destination
Issues
1 July 2022
-
Cover Image
Cover Image
The tumor microenvironment (TME) harbors cancer-associated fibroblasts (CAF) and other factors that promote tumor growth and progression. Modeling the TME is challenging given mouse models lack human CAF and extracellular matrix (ECM) components, and two-dimensional cell cultures fail to recapitulate integral in vivo structures. Addressing these challenges could facilitate studies capable of discovering novel TME-tumor interactions and therapeutic targets therein. In their study, Singh and colleagues devised a three-dimensional organotypic model, containing human triple-negative breast cancer (TNBC) cells, CAF, and an extracellular collagen matrix in an effort to study TME-TNBC interactions. The cover depicts a confocal image of the three-dimensional model. TNBC cells (green) form a mass embedded in a collagen matrix (cyan) containing dispersed CAF (red), reproducing spatial organization of native breast tumors. The authors utilized the model to demonstrate that CAF promote TNBC ECM invasion through a specific HGF-cMET signaling mechanism. This phenomenon is visible as green TNBC cell dissemination from the mass into the cyan collagen matrix in the cover image. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
ISSN 1541-7786
EISSN 1557-3125
Molecular Cancer Research
Table of Contents
Highlights
Rapid Impact
Identifying Phased Mutations and Complex Rearrangements in Human Prostate Cancer Cell Lines through Linked-Read Whole-Genome Sequencing
Minh-Tam Pham; Anuj Gupta; Harshath Gupta; Ajay Vaghasia; Alyza Skaist; McKinzie A. Garrison; Jonathan B. Coulter; Michael C. Haffner; S. Lilly Zheng; Jianfeng Xu; Christina DeStefano Shields; William B. Isaacs; Sarah J. Wheelan; William G. Nelson; Srinivasan Yegnasubramanian
Cancer Genes and Networks
Mitochondrial Dysfunction Is a Driver of SP-2509 Drug Resistance in Ewing Sarcoma
E. John Tokarsky; Jesse C. Crow; Lillian M. Guenther; John Sherman; Cenny Taslim; Gabriela Alexe; Kathleen I. Pishas; Galen Rask; Blake S. Justis; Ana Kasumova; Kimberly Stegmaier; Stephen L. Lessnick; Emily R. Theisen
Cancer “-omics”
New Horizons in Cancer Biology
Signal Transduction and Functional Imaging
mTOR Inhibition and T-DM1 in HER2-Positive Breast Cancer
David Casadevall; Anna Hernández-Prat; Sara García-Alonso; Oriol Arpí-Llucià; Silvia Menéndez; Mengjuan Qin; Cristina Guardia; Beatriz Morancho; Francisco Javier Sánchez-Martín; Sandra Zazo; Elena Gavilán; Mohammad A. Sabbaghi; Pilar Eroles; Juan Miguel Cejalvo; Ana Lluch; Federico Rojo; Atanasio Pandiella; Ana Rovira; Joan Albanell
Tumor Microenvironment and Immunobiology
DNA-PK Inhibition and Radiation Promote Antitumoral Immunity through RNA Polymerase III in Pancreatic Cancer
Weiwei Wang; Matthew T. McMillan; Xinyi Zhao; Zhuwen Wang; Long Jiang; David Karnak; Fatima Lima; Joshua D. Parsels; Leslie A. Parsels; Theodore S. Lawrence; Timothy L. Frankel; Meredith A. Morgan; Michael D. Green; Qiang Zhang
Retractions
Journal Archive
Molecular Cancer Research
(2002-Present; volumes 1-current)Published monthly since November, 2002.
(ISSN 0008-5472)
Cell Growth & Differentiation
(1990-2002; volumes 1-13)Published monthly 1990- September, 2002.
(ISSN 1044-9523)
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.